CD274 and breast cancer: In the absence of any published datasets of BC patients receiving immunotherapy, we utilized urothelial cancer dataset that received anti-PD-L1 therapy (IMvigor210), in order to test our functional gene set-based prognostic model to classify high- and low-risk groups.